The US Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) for Praluent (alirocumab) Injection, a PCSK9 inhibitor.
Filed by US biotech Regeneron Pharmaceutical (Nasdaq: REGN) and French partner Sanofi (Euronext: SAN), the sBLA outlines a proposed update to the Prescribing Information to include the effect of Praluent in reducing the overall risk of major adverse cardiovascular events (MACE). MACE is an umbrella term that includes heart attack, ischemic stroke, death from coronary heart disease and unstable angina requiring hospitalization. The FDA set a Prescription Drug User Fee Act (PDUFA) action date of April 28, 2019.
In its current indications, Praluent generated second quarter 2018 sales of 62 million euros ($72 million) for Sanofi, whose shares edged up 0.94% to 73.96 euros in morning trading today.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze